Apellis Pharmaceuticals (NASDAQ:APLS) Given New $41.00 Price Target at Mizuho

Apellis Pharmaceuticals (NASDAQ:APLS) had its price objective raised by Mizuho from $20.00 to $41.00 in a research note released on Thursday morning,Benzinga reports. They currently have a neutral rating on the stock.

A number of other equities analysts have also weighed in on the stock. Barclays upped their target price on shares of Apellis Pharmaceuticals from $24.00 to $41.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Wedbush decreased their target price on Apellis Pharmaceuticals from $20.00 to $18.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 25th. Stifel Nicolaus dropped their price target on Apellis Pharmaceuticals from $55.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, December 19th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $41.00 target price (up from $37.00) on shares of Apellis Pharmaceuticals in a research report on Wednesday. Finally, HC Wainwright cut shares of Apellis Pharmaceuticals from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $48.00 to $41.00 in a research note on Wednesday. Five research analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Apellis Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $34.11.

Apellis Pharmaceuticals Stock Up 0.0%

Shares of APLS stock opened at $40.41 on Thursday. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.14 and a quick ratio of 2.70. Apellis Pharmaceuticals has a one year low of $16.10 and a one year high of $40.48. The company’s fifty day moving average price is $21.87 and its 200-day moving average price is $22.83. The company has a market capitalization of $5.17 billion, a price-to-earnings ratio of 310.87 and a beta of -0.19.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Tuesday, February 24th. The company reported $0.47 earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.86. Apellis Pharmaceuticals had a net margin of 2.23% and a return on equity of 8.20%. The company had revenue of $199.91 million during the quarter, compared to the consensus estimate of $199.28 million. During the same quarter in the prior year, the firm posted ($0.29) EPS. Apellis Pharmaceuticals’s quarterly revenue was down 5.9% compared to the same quarter last year. Sell-side analysts expect that Apellis Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Insider Buying and Selling at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, insider Mark Jeffrey Delong sold 3,371 shares of the firm’s stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $21.77, for a total transaction of $73,386.67. Following the transaction, the insider owned 78,353 shares of the company’s stock, valued at approximately $1,705,744.81. This trade represents a 4.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO James George Chopas sold 2,064 shares of the business’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total transaction of $44,933.28. Following the completion of the transaction, the chief accounting officer directly owned 49,805 shares of the company’s stock, valued at $1,084,254.85. This trade represents a 3.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 115,537 shares of company stock worth $2,486,082 over the last quarter. Insiders own 6.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Jones Financial Companies Lllp raised its stake in shares of Apellis Pharmaceuticals by 206.8% during the 3rd quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company’s stock worth $46,000 after acquiring an additional 1,373 shares in the last quarter. Osaic Holdings Inc. lifted its holdings in shares of Apellis Pharmaceuticals by 141.2% during the 2nd quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock valued at $47,000 after purchasing an additional 1,570 shares during the last quarter. Allworth Financial LP boosted its position in shares of Apellis Pharmaceuticals by 64.1% in the 3rd quarter. Allworth Financial LP now owns 2,194 shares of the company’s stock worth $50,000 after purchasing an additional 857 shares in the last quarter. Quantbot Technologies LP acquired a new stake in Apellis Pharmaceuticals in the third quarter worth about $64,000. Finally, EverSource Wealth Advisors LLC grew its stake in shares of Apellis Pharmaceuticals by 338.5% during the second quarter. EverSource Wealth Advisors LLC now owns 5,429 shares of the company’s stock worth $94,000 after acquiring an additional 4,191 shares during the last quarter. Hedge funds and other institutional investors own 96.29% of the company’s stock.

More Apellis Pharmaceuticals News

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: Biogen agreed to acquire Apellis for about $5.6B, bringing immediate valuation certainty (cash consideration of $41.00/share plus contingent value rights tied to SYFOVRE sales). Biogen to Acquire Apellis (Zacks)
• Positive Sentiment: Market reaction: APLS shares jumped dramatically on the deal announcement as traders priced in the buyout premium and CVR upside. APLS stock soars 140% (MSN)
• Neutral Sentiment: Several banks raised price targets to roughly $41 (Mizuho, Barclays, JPMorgan), but many gave neutral/equal-weight ratings — implying limited upside above the deal price and signaling more conservative near-term expectations. Analyst target updates (Benzinga)
• Neutral Sentiment: Industry commentary and comparisons highlight Apellis’ assets (SYFOVRE and immunology pipeline) as strategic for acquirers — useful context for longer‑term value but not an immediate catalyst beyond the acquisition. Comparing Apellis with competitors (Benzinga)
• Negative Sentiment: Major sell‑side shops have rapidly cut ratings (several downgrades from strong-buy/buy to hold/neutral), reflecting concerns about near-term growth post-sale, which could dampen secondary trading sentiment ahead of deal close. JP Morgan Downgrades Apellis (MSN)
• Negative Sentiment: Two law firms have launched shareholder investigations into the proposed sale (pricing and process), adding legal/closing‑risk uncertainty that could affect timing or terms. Shareholder investigation (PR Newswire)

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.